These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33871787)
1. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma. Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787 [No Abstract] [Full Text] [Related]
2. Killing Two Birds with One Stone: the Therapeutic Role of Ibrutinib in Schnitzler Syndrome. Wang C J Clin Immunol; 2021 Oct; 41(7):1706-1707. PubMed ID: 34313913 [No Abstract] [Full Text] [Related]
3. Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome. Huang Y; Wang Y; Yu F; Mao X; Wang B; Li J; Li L Front Immunol; 2022; 13():894464. PubMed ID: 35514998 [TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526 [No Abstract] [Full Text] [Related]
5. Case report: Successful treatment with tofacitinib and colchicine in a patient with Schnitzler syndrome. Li M; Chen YW; Shen A; Xie YX; Wu Y; Zeng X; Leong PY Int J Rheum Dis; 2023 Jan; 26(1):160-163. PubMed ID: 36261877 [TBL] [Abstract][Full Text] [Related]
6. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336 [TBL] [Abstract][Full Text] [Related]
8. [Schnitzler syndrome: A review of literature, the authors' observation, and experience with the interleukin-1 inhibitor canakinumab]. Salugina SO; Gorodetsky VR; Fedorov ES; Lopatina NE; Evsikova MD Ter Arkh; 2017; 89(11):111-115. PubMed ID: 29260755 [TBL] [Abstract][Full Text] [Related]
10. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy. Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758 [No Abstract] [Full Text] [Related]
11. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. Ryan JG; de Koning HD; Beck LA; Booty MG; Kastner DL; Simon A J Allergy Clin Immunol; 2008 Jan; 121(1):260-2. PubMed ID: 17936890 [No Abstract] [Full Text] [Related]
12. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction. Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264 [No Abstract] [Full Text] [Related]
13. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report]. Wang L; Li X; He YZ Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461 [No Abstract] [Full Text] [Related]
14. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib. Kallam A; Hansen N; Bierman P Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203 [No Abstract] [Full Text] [Related]
15. Tocilizumab as a potential treatment in Schnitzler syndrome. Kluger N; Bessis D; Guillot B Med Hypotheses; 2009 Apr; 72(4):479-80. PubMed ID: 19150755 [No Abstract] [Full Text] [Related]
16. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib]. Okahashi N; Uchihara M; Hoshino E Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449 [TBL] [Abstract][Full Text] [Related]
17. Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients? Alsuliman T; Faict S; Malard F; Genthon A; Brissot E; Van de Wyngaert Z; Ikhlef S; Banet A; Lapusan S; Sestili S; Corre E; M'hammedi-Bouzina F; Schaeffer L; Legrand O; Dulery R; Mohty M; Marjanovic Z Curr Res Transl Med; 2021 Jan; 69(1):103273. PubMed ID: 33460953 [No Abstract] [Full Text] [Related]
19. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. T Low J; B Peters K CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313 [TBL] [Abstract][Full Text] [Related]
20. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]